Allergy Therapeutics appoints Abbott’s Licensing and Acquisitions Vice President to its Board
February 8, 2017Allergy Therapeutics has appointed Jeff Barton to the Company’s Board as a Non-Executive Director, nominated by Abbott Laboratories in replacement of Mr Jean-Yves Pavee who retires from the Board, both effective after close of business 7 February 2017.
Jeff Barton currently serves as Vice President, Licensing and Acquisitions, at Abbott. During his time in this role, Abbott has executed several strategically important transactions including the acquisition of St. Jude Medical, CFR Pharmaceuticals and Veropharm.
Peter Jensen, Chairman of Allergy Therapeutics, commented: “(Jeff Barton) brings extensive commercial experience, particularly in the United States, which will be valuable to our Company as we continue to execute our global strategy.”
